Insulin-like growth factor 2 targets IGF1R signaling transduction to facilitate metastasis and imatinib resistance in gastrointestinal stromal tumors.

IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY
De-Gang Li, Jia-Peng Jiang, Fan-Ye Chen, Wei Wu, Jun Fu, Gong-He Wang, Yu-Bo Li
{"title":"Insulin-like growth factor 2 targets IGF1R signaling transduction to facilitate metastasis and imatinib resistance in gastrointestinal stromal tumors.","authors":"De-Gang Li, Jia-Peng Jiang, Fan-Ye Chen, Wei Wu, Jun Fu, Gong-He Wang, Yu-Bo Li","doi":"10.4251/wjgo.v16.i8.3585","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Gastrointestinal stromal tumors (GISTs) are typical gastrointestinal tract neoplasms. Imatinib is the first-line therapy for GIST patients. Drug resistance limits the long-term effectiveness of imatinib. The regulatory effect of insulin-like growth factor 2 (IGF2) has been confirmed in various cancers and is related to resistance to chemotherapy and a worse prognosis.</p><p><strong>Aim: </strong>To further investigate the mechanism of IGF2 specific to GISTs.</p><p><strong>Methods: </strong>IGF2 was screened and analyzed using Gene Expression Omnibus (GEO: GSE225819) data. After IGF2 knockdown or overexpression by transfection, the phenotypes (proliferation, migration, invasion, apoptosis) of GIST cells were characterized by cell counting kit 8, Transwell, and flow cytometry assays. We used western blotting to evaluate pathway-associated and epithelial-mesenchymal transition (EMT)-associated proteins. We injected transfected cells into nude mice to establish a tumor xenograft model and observed the occurrence and metastasis of GIST.</p><p><strong>Results: </strong>Data from the GEO indicated that IGF2 expression is high in GISTs, associated with liver metastasis, and closely related to drug resistance. GIST cells with high expression of IGF2 had increased proliferation and migration, invasiveness and EMT. Knockdown of IGF2 significantly inhibited those activities. In addition, OE-IGF2 promoted GIST metastasis <i>in vivo</i> in nude mice. IGF2 activated IGF1R signaling in GIST cells, and IGF2/IGF1R-mediated glycolysis was required for GIST with liver metastasis. GIST cells with IGF2 knockdown were sensitive to imatinib treatment when IGF2 overexpression significantly raised imatinib resistance. Moreover, 2-deoxy-D-glucose (a glycolysis inhibitor) treatment reversed IGF2 overexpression-mediated imatinib resistance in GISTs.</p><p><strong>Conclusion: </strong>IGF2 targeting of IGF1R signaling inhibited metastasis and decreased imatinib resistance by driving glycolysis in GISTs.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334037/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Gastrointestinal Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4251/wjgo.v16.i8.3585","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Gastrointestinal stromal tumors (GISTs) are typical gastrointestinal tract neoplasms. Imatinib is the first-line therapy for GIST patients. Drug resistance limits the long-term effectiveness of imatinib. The regulatory effect of insulin-like growth factor 2 (IGF2) has been confirmed in various cancers and is related to resistance to chemotherapy and a worse prognosis.

Aim: To further investigate the mechanism of IGF2 specific to GISTs.

Methods: IGF2 was screened and analyzed using Gene Expression Omnibus (GEO: GSE225819) data. After IGF2 knockdown or overexpression by transfection, the phenotypes (proliferation, migration, invasion, apoptosis) of GIST cells were characterized by cell counting kit 8, Transwell, and flow cytometry assays. We used western blotting to evaluate pathway-associated and epithelial-mesenchymal transition (EMT)-associated proteins. We injected transfected cells into nude mice to establish a tumor xenograft model and observed the occurrence and metastasis of GIST.

Results: Data from the GEO indicated that IGF2 expression is high in GISTs, associated with liver metastasis, and closely related to drug resistance. GIST cells with high expression of IGF2 had increased proliferation and migration, invasiveness and EMT. Knockdown of IGF2 significantly inhibited those activities. In addition, OE-IGF2 promoted GIST metastasis in vivo in nude mice. IGF2 activated IGF1R signaling in GIST cells, and IGF2/IGF1R-mediated glycolysis was required for GIST with liver metastasis. GIST cells with IGF2 knockdown were sensitive to imatinib treatment when IGF2 overexpression significantly raised imatinib resistance. Moreover, 2-deoxy-D-glucose (a glycolysis inhibitor) treatment reversed IGF2 overexpression-mediated imatinib resistance in GISTs.

Conclusion: IGF2 targeting of IGF1R signaling inhibited metastasis and decreased imatinib resistance by driving glycolysis in GISTs.

胰岛素样生长因子2靶向IGF1R信号转导,促进胃肠道间质瘤的转移和伊马替尼耐药性。
背景:胃肠道间质瘤(GIST)是典型的胃肠道肿瘤。伊马替尼是 GIST 患者的一线治疗药物。耐药性限制了伊马替尼的长期疗效。胰岛素样生长因子2(IGF2)的调节作用已在多种癌症中得到证实,并与化疗耐药性和预后不良有关:方法:利用Gene Expression Omnibus(GEO:GSE225819)数据对IGF2进行筛选和分析。通过转染敲除或过表达 IGF2 后,GIST 细胞的表型(增殖、迁移、侵袭、凋亡)通过细胞计数试剂盒 8、Transwell 和流式细胞术检测进行表征。我们用 Western 印迹法评估了通路相关蛋白和上皮-间质转化(EMT)相关蛋白。我们将转染细胞注入裸鼠体内,建立肿瘤异种移植模型,并观察 GIST 的发生和转移情况:来自 GEO 的数据表明,IGF2 在 GIST 中高表达,与肝转移有关,并与耐药性密切相关。高表达 IGF2 的 GIST 细胞增殖、迁移、侵袭性和 EMT 增高。敲除 IGF2 能显著抑制这些活性。此外,OE-IGF2 还能促进裸鼠体内 GIST 的转移。IGF2激活了GIST细胞中的IGF1R信号转导,IGF2/IGF1R介导的糖酵解是GIST肝转移的必要条件。IGF2敲除的GIST细胞对伊马替尼治疗敏感,而IGF2过表达则会显著增加伊马替尼的耐药性。此外,2-脱氧-D-葡萄糖(一种糖酵解抑制剂)治疗可逆转IGF2过表达介导的GIST对伊马替尼的耐药性:结论:IGF2靶向IGF1R信号转导可抑制转移,并通过促进糖酵解降低GIST对伊马替尼的耐药性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
World Journal of Gastrointestinal Oncology
World Journal of Gastrointestinal Oncology Medicine-Gastroenterology
CiteScore
4.20
自引率
3.30%
发文量
1082
期刊介绍: The World Journal of Gastrointestinal Oncology (WJGO) is a leading academic journal devoted to reporting the latest, cutting-edge research progress and findings of basic research and clinical practice in the field of gastrointestinal oncology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信